NEW YORK (GenomeWeb News) – MDS said today that its MDS Analytical Technologies unit has acquired cell imaging products firm Blueshift Biotechnologies for $13 million.
Sunnyvale, Calif.-based Blueshift makes the IsoCyte benchtop instrument, which performs rapid image analysis of large populations of cells in a microtiter plate whole-well format. According to Toronto-based MDS, Blueshift has placed 14 of the IsoCyte instruments with academic, biotech, and pharmaceutical customers.
“This acquisition fills a gap in our current product portfolio, allowing us to offer our pharmaceutical research customers fast and simple cellular analysis with a line of instrumentation that images the whole well at true high throughput screening rates,” Andy Boorn, president of MDS Analytcial Technologies, said in a statement.
The firms did not disclose Blueshift’s annual revenues.